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I am deeply honored to receive the Allan Award from
the American Society of Human Genetics and to join
the ranks of the 38 illustrious awardees who have pre-
ceded me. The last time Arno Motulsky and I were both
together on this podium, I was introducing him on his
receipt of the Society’s Education Award. That was a
great pleasure for me and quite appropriate, because he
was the teacher and I was the student. Now, things are
the other way around, and it is an even greater pleasure
for the student to be introduced by his teacher.
I have been present at nearly all of the Allan Award
addresses, the first one being given by Oliver Smithies
as an after-dinner talk at the Society banquet in 1964.
Oliver’s presentation was memorable for me because he
gave us a little flute concert after concluding his talk.
For a fleeting second I thought that I might emulate him
and play my ’cello for you—but you will be happy to
hear that I thought better of it.
There have been many other memorable talks over
the years, and one that is still particularly vivid in my
mind was given by Jerome Lejeune in 1969, ten years
after the discovery of trisomy 21 (Lejeune 1970). The
1969 meeting, which was in San Francisco, was notable
for more that Lejeune’s talk, since it had the added at-
traction of a San Francisco special—a gentle earthquake!
More about all of this later.
My first real exposure to human genetics came in con-
versations with Kurt Benirschke while I was in medical
school. Kurt has been the legendary geneticist of the San
Diego Zoo. It was from him that I learned about the
sex life of nine-banded armadillos, which he allegedly
kept in his basement, and heard about Tjio and Levan’s
work on the human karyotype and about the early dis-
coveries of the chromosomal basis of Down syndrome
and other disorders. However, my turn toward genetics
as a career came about in a somewhat unusual way.
When I appeared for the first time in Christian Anfinsen’s
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laboratory in the National Heart Institute, I asked him
what he wanted me to do. All that he said to me was,
“Refold trypsin,” and he then promptly went on a trip
to Israel. What he meant was that I was supposed to
reduce the six disulfide bonds of trypsin with mercap-
toethanol, denature it completely in urea, and then see
whether I could get it to reacquire enzymatic activity
and, by inference, its native structure (fig. 1). All of this
was by way of adding further support to Anfinsen’s the-
ory, for which he subsequently got the Nobel Prize, that
the three-dimensional structure of a protein is deter-
mined by the linear sequence of amino acids in the poly-
peptide chain (Anfinsen 1973). While now part of the
dogma of molecular biology, this was a very controver-
sial issue at the time. Anfinsen’s challenge to me and the
work that ensued from it were my first introduction to
genetics in action, since what was really being studied
was the genetic control of protein structure.
During the middle of my tenure at the NIH [the Na-
tional Institutes of Health], I spent a year in Seattle as
a fellow with Arno Motulsky. This was to be my only
formal training in human and medical genetics. It was
during this time that we began our work together—
along with George Martin—on Werner syndrome. This
work was stimulated by the woman in figure 2, who
was 48 years old when the picture was taken. As hard
as we tried to think about what the genetic defect might
be (Epstein et al. 1966), it took another thirty years
before it was identified, by the Seattle group, as a mu-
tation in a helicase gene (Yu et al. 1996).
Arno’s mentorship has been instrumental in much that
I have been able to accomplish since then. Both Chris
Anfinsen and Arno Motulsky had a similar style of su-
pervising their trainees—they led by example and by
establishing expectations and standards of excellence. It
was up to the trainees to figure out how to get things
done.
My time in Seattle convinced me that I did not want
to be a protein chemist—even a genetic protein chemist
—so, eventually, my wife, Lois, our two and a half chil-
dren, and I headed west to San Francisco where I started
down two parallel tracks. The first track involved a con-
siderable gamble on my part. Without any prior experi-
ence or training, I switched to the mouse as an experi-
mental system. To be more precise, I chose to work on
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Figure 1 The experimental denaturation (UNFOLDING) and
renaturation (REFOLDING) of a disulfide bond–containing protein,
to demonstrate that the three-dimensional structure of the protein is
determined by its primary amino acid sequence. Reprinted, by per-
mission, from Epstein et al. (1963). ( 1963 by Cold Spring Harbor
Laboratory Press.)
Figure 2 Forty-eight-year-old woman with Werner syndrome,
an autosomal recessive disorder caused by a helicase mutation that
produces a caricature of aging. Reprinted, by permission, from Epstein
et al. (1966). ( 1966 by Lippincott Williams & Wilkins.)
the preimplantation mouse embryo (fig. 3). While still at
the NIH, I had been very much taken by the work of
many of the mouse developmental geneticists of the
time—Salome Waelsch, Beatrice Mintz, Tibby Russell,
and Dorothea Bennett were among the leaders. Of these,
Beatrice Mintz was particularly influential in that she
showed how both genetics and embryo manipulation
could be used in combination to study various aspects of
development. I was quite impressed by her ability to gen-
erate chimeric mice by the aggregation of early embryos,
a technique that I was to use later in my own work (Ep-
stein et al. 1982b) (fig. 4).
To get into the preimplantation mouse system, I fol-
lowed the lead of Ralph Brinster, who had been able to
measure enzyme activities in just one or a few preimplan-
tation mouse embryos (Brinster 1965, 1966). Since I
knew, from my earlier protein chemistry days, how to
measure enzyme activities, this was a comfortable way
to begin. The trick was to find really sensitive assays,
and two that turned out to be particularly useful were
for the X-linked enzymes: glucose-6-phosphate dehy-
drogenase and hypoxanthine-guanine phosphoribosyl-
transferase. Using these assays, we were able to show
that embryonic X-inactivation starts at about the time
of implantation, initially with the formation of the tro-
phectoderm, and is reversed during oogenesis (fig. 5)
(Epstein 1969, 1972, 1981; Epstein et al. 1978). The
effect of the lack of inactivation during oogenesis is to
make the eggs from XO females functionally aneuploid
and haploinsufficient, which, I believe, accounts for their
premature degeneration. This work on the X chromo-
some was my first foray into matters of gene dosage.
While all of this was going on, I was engaged in the
second track of my academic life, as a clinical geneticist.
In this capacity, I encountered the entire gamut of genetic
disorders and birth defects and became involved in the
establishment of a prenatal-diagnosis service and of sev-
eral satellite genetic-counseling clinics. Of the many clin-
ical disorders that I dealt with, the one that most cap-
tured my research attention was Down syndrome, and
Edward Schneider, a postdoctoral fellow at the time,
prepared matched pairs of trisomic and sibling fibro-
blasts for some early experiments (Schneider and Epstein
1972). With these cells in hand, we were in a position
to begin to look at the effects of a change in gene dosage
in Down syndrome when Chris Tan, Jay Tischfield, and
Frank Ruddle mapped the first two genes to human chro-
mosome 21 in 1973 (Tan et al. 1973). Although they
had different names at the time, we now know these
two genes to be SOD1, the gene for CuZn superoxide
dismutase (SOD), and IFNAR1, the gene for the binding
subunit of the interferon-alpha receptor. Because my
wife, Lois, had by then become an internationally rec-
ognized expert on interferon and knew how to carry out
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Figure 3 Scanning and transmission micrographs of a preim-
plantation mouse embryo at the blastocysts stage. Reprinted, by per-
mission, from Calarco and Epstein (1973).
Figure 4 A trisomy 17 ↔ diploid chimera generated by preim-
plantation embryo aggregation, by the method developed by Beatrice
Mintz (1972). Reprinted, by permission, from Epstein et al. (1982b).
( 1982 by the National Academy of Sciences, U.S.A.)
the appropriate interferon-response assays, we chose to
pursue the interferon-receptor gene first.
Our investigations revealed that trisomy 21 cells bind
more interferon—just about 50% more, in fact (fig. 6)
(Epstein et al. 1982a), as was expected—and, as a result,
are more sensitive to it (Epstein and Epstein 1976; Ep-
stein et al. 1980). In fact, the trisomic cells could be as
much as 10 times more sensitive to interferon (Weil et
al. 1980). This was taken to be a concrete demonstration
of how a change in the dosage of a single gene of the
degree occurring in trisomy 21 could have demonstrable
functional consequences. (The actual situation may be
somewhat more complicated because both the inter-
feron-binding and signal-transducing subunits of the in-
terferon-a receptor are encoded by contiguous loci on
chromosome 21.) It was legitimate, therefore, to think
in terms of the effects of the increased dosage of specific
genes in producing the aneuploid phenotype.
At this point, the two lines of research—mouse ge-
netics and human trisomy 21—converged, with the
bridge between the two being provided by the work of
Alfred Gropp, a German pathologist interested in hunt-
ing and cytogenetics. These interests brought him to an
isolated valley in the Italian Alps in which lives Mus
poschiavinus, the so-called “tobacco mouse,” which has
only 26 chromosomes, rather than the usual 40, with
seven pairs of Robertsonian fusion chromosomes (fig.
7). Gropp transferred many of these Robertsonians to
regular laboratory mice and then devised a method for
generating each of the mouse trisomies at a relatively
high frequency (Gropp et al. 1975). This made it possible
to consider, for the first time, the development of a mouse
model of human trisomy 21.
There were several reasons for wanting to have such
a model. For both practical and ethical reasons, we were
restricted in our ability to study humans with Down
syndrome. Only a few types of cells could be looked at,
and there was no real access to the CNS. By contrast,
all cells and tissues—including, in particular, the brain
—could be studied in the mouse, and we would be able
to exercise tight genetic control to reduce the effects of
a variable background. And, although we did not know
it at the time, we would eventually have the ability to
manipulate the mouse genome almost at will. Finally,
and perhaps of greatest importance, an appropriate
model would permit potential therapeutic approaches
based on a detailed knowledge of relationship between
genotype and phenotype to be rationally designed and
tested.
We were ready to start on the development of a model,
but there were two questions that had to be answered.
First, given the number of chromosomal rearrangements
that have occurred since the evolutionary divergence of
humans and mice, would enough human chromosome
21 genes be syntenic in the mouse to make any single
mouse trisomy a useful model? And, if so, which mouse
chromosome most closely resembles human chromo-
some 21?
The answers to both questions required the mapping
of known human chromosome 21 genes into the mouse,
and, when David Cox (then a fellow in my laboratory),
Lois Epstein, and I began this work, we still knew of
only two genes—the same SOD and interferon-receptor
genes I mentioned earlier. However, good fortune smiled
on our efforts, and it turned out that these two genes
are both on mouse chromosome 16 (Cox et al. 1980).
With time, it has been shown that all of the genes on
the long arm of human chromosome 21 down to the
Mx locus in mid-21q22.3 are syntenic on mouse chro-
mosome 16 (fig. 8). From examining the complete se-
quence of human chromosome 21, we now know that
this corresponds to more than half of the ∼225 known
and inferred genes on this chromosome (Roger Reeves,
personal communication). The remaining human chro-
mosome 21 genes are present on mouse chromosomes
10 and 17. However, from the work of Julie Korenberg,
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Figure 5 The life cycle of the X chromosome, showing that both
X chromosomes are active during oogenesis and early embryonic de-
velopment, with X-inactivation first occurring at the time of implan-
tation. Reprinted, by permission, from Epstein (1981). ( 1981 by
Lippincott Williams & Wilkins.)
Figure 6 Interferon-a binding and antiviral sensitivity, in trisomy
21 cells. A, The binding of interferon-a to the interferon-a receptor in
matched trisomy 21 and diploid fibroblasts. In the experiment shown,
the trisomic cells bound 1.6 times as much interferon as do the diploid
cells, which is very close to the theoretical value of 1.5 that is expected
from the increase in copy number of the receptor gene from 2 to 3.
Reprinted, by permission, from Epstein et al. (1982a). ( 1982 by Ac-
ademic Press.) B, Increased sensitivity of trisomy 21 fibroblasts to the
antiviral effect of interferon-a. In the experiment shown, sensitivity was
increased by greater than 10-fold, but in several experiments the median
increase was close to 6-fold. Reprinted, by permission, from Weil et al.
(1980). ( 1980 by Mary Ann Liebert, Inc.)
who had been analyzing the relationships between phe-
notype and genotype in the rare persons with segmental
trisomy 21, we learned that many aspects of the Down
syndrome phenotype—including dysmorphic changes in
the craniofacies, hands, and feet; duodenal stenosis; hy-
potonia; lax ligaments; and mental retardation—can
also occur with segmental trisomy—as in patients JS and
KJ, in fig. 9—for just that region of human chromosome
21 that is in common with mouse chromosome 16.
All of this suggested that mouse trisomy 16 would be
a valid genetic model for human trisomy 21, and the
phenotype appeared to confirm this—congenital heart
disease with an atrioventricular canal and conotruncal
anomalies, thymic hypoplasia, delayed maturation of the
immune system, craniofacial abnormalities, and midges-
tational edema (fig. 10) (Epstein et al. 1985; Epstein 1986;
Berger and Epstein 1989). If anything, the defects in the
trisomic mouse were even more severe than in Down syn-
drome, and it was eventually realized that the trisomy 16
mouse was too good to be true—not because the human
chromosome 21 genes were not there, but because too
many other genes were! The principal problem is that
mouse chromosome 16, in addition to having a large pro-
portion of the human chromosome 21q genes, also has
appreciable amounts of sequence homologous to regions
of four other human chromosomes in its proximal 80%
(fig. 8). Therefore, while still quite useful for studying
various aspects of the effects of aneuploidy, complete
mouse trisomy 16 was not the best model of human tri-
somy 21. What would be better would be a mouse with
segmental trisomy 16—trisomic for just that region of
mouse chromosome 16 that is homologous to human
chromosome 21—and this is just what Muriel Davisson,
at the Jackson Laboratory, was able to produce.
The new mouse, designated “Ts65Dn” (“Ts65” for
short), was the result of a radiation-induced transloca-
tion between parts of chromosomes 16 and 17 that gave
rise to a tertiary trisomy (Reeves et al. 1995; Akeson et
al. 2001). This mouse is viable but tends to be small.
Its immune system is in reasonably good shape, and there
are no gross congenital malformations—in particular, no
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Figure 7 Fluorescent-banded karyotype (top) and somewhat
fanciful picture ofM. poschiavinus, the tobacco mouse (bottom). These
pictures were obtained from the late Prof. Alfred Gropp, of Lu¨beck,
Germany.
heart disease. As in human trisomy 21, the males are
sterile, but it is possible to breed Ts65 mice, with some
difficulty, from trisomic females, although not on an in-
bred background.
How good is Ts65 as a model for Down syndrome?
Quite good, I would say, and, in at least two areas, the
CNS and the craniofacial skeleton, the Ts65 mouse ex-
hibits very interesting and highly relevant abnormalities.
Among the several abnormalities of the nervous system
that have been found, we have been examining, in a
longtime collaboration with William Mobley (formerly
of UCSF [University of California–San Francisco] and
now at Stanford), the status of the basal forebrain cho-
linergic neurons in the medial septal nucleus. These neu-
rons are of particular interest because of their vulnera-
bility in Alzheimer disease, a late consequence of trisomy
21. Mobley and his colleagues have shown that, in the
trisomic brains, there is a decrease, with time, in the
relative number and size of functional cholinergic neu-
rons (Holtzman et al. 1993, 1996; Cooper et al. 2001).
Nerve growth factor (NGF) is a trophic factor made in
the hippocampus that is transported by retrograde ax-
onal transport to the cell bodies in the basal forebrain.
When the rate of this retrograde transport was deter-
mined, it was found to be significantly decreased in the
trisomic brain (Cooper et al. 2001). This finding sug-
gested an experiment with obvious therapeutic impli-
cations. If the loss of cholinergic neurons is indeed the
result of a deficiency of NGF, what effect would treat-
ment with NGF have? This experiment was carried out
by introducing NGF into the ventricles of the Ts65 mice
through a cannula attached to an osmotic minipump,
and the effect was quite gratifying (Cooper et al. 2001).
The atrophy of the cholinergic neurons was partially
reversed, as is indicated by the arrow in figure 11, and
the number of neurons actually increased, indicating
that, although they had disappeared functionally, they
had not really disappeared anatomically. Dr. Mobley and
his group are continuing these studies.
In our studies of the interferon-response system that
I described earlier, it was possible to demonstrate specific
functional consequences of the increased dosage of just
a single gene. Furthermore, an analysis of the specificity
and reproducibility of the patterns of abnormalities in
the various trisomies and monosomies, even in the face
of individual variability, has convinced me that the aneu-
ploid phenotypes that we see are truly the result of the
particular genes that are genetically unbalanced when a
duplication or deletion is present and are not the result
of some kind of random noise or general loosening up
of developmental homeostasis (Epstein 1986). There-
fore, although a phenotype is undoubtedly produced by
the interaction of the effects—some large, some small
—of many of the unbalanced genes, it is valid to inves-
tigate the contributions of individual loci to the phe-
notype. This conclusion suggested a second approach to
the modeling of Down syndrome, and that was by in-
vestigating the imbalance of genes individually by the
generation of transgenic mice.
When Yoram Groner and his colleagues at the Weiz-
mann Institute in Israel reported the cloning of the first
human chromosome 21 gene—our old friend, SOD1—it
became possible to do just that, and we collaborated to
produce the first series of mice transgenic for CuZn SOD
(Epstein et al. 1987). Groner used these mice to look
for abnormalities that might resemble those found in
persons with Down syndrome, and he found several—
abnormalities of the myoneural junctions in the tongue,
an impairment in the uptake of serotonin by platelets,
and a decreased synthesis of prostaglandins D2 and E2
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Figure 8 Syntenic region in common between human chromosome 21 (HSA 21) and mouse chromosome 16 (MMU 16) that forms the
basis for the development of the trisomy 16 mouse models of Down syndrome. The other mouse chromosome regions orthologous to human
chromosome 21 and other human chromosome regions orthologous to mouse chromosome 16 are shown, as is the location of the Ts65Dn
breakpoint aboveApp. The first two human chromosome 21 loci mapped to mouse chromosome 16 by Cox et al. (1980)—SOD1 and IFNAR—are
marked with by asterisks (*). This figure is a modification of comparative maps kindly provided by Roger Reeves and published in Richtsmeier
et al. (2000). Reprinted by permission. ( 2000 by Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.)
(Groner 1995). We, on the other hand, set out to test
Pierre-Marie Sinet’s hypothesis that an increase in CuZn
SOD activity might have deleterious effects on the nervous
system because of an enhancement of the production of
hydrogen peroxide from the superoxide that is generated
within cells, the conversion of O2
 to H2O2 being the
function of the enzyme (Sinet 1982). This proved not to
be the case, at least in the mouse brain, but these studies
led us in a direction entirely different from Down syn-
drome. Having these transgenic animals in hand, we
became quite interested in the role of the SODs them-
selves—I use the plural because there are actually three
different dismutases in mammals (CuZn SOD, Mn SOD,
and EC SOD)—in longevity and in protecting against
various forms of oxidative stress, and what we found is
that, contrary to what was observed in fruit flies and
proclaimed in the headlines a few years back (Kotulak
and Gorner 1992), an increase in CuZn SOD activity
by three- to fivefold did not prolong life span in trans-
genic mice (fig. 12) (Huang et al. 2000). However, stud-
ies carried out in collaboration with many different
groups have indicated that, with just one exception (Ful-
lerton et al. 1998), increased CuZn SOD activity does
protect, in a number of different experimental para-
digms, against acute oxidative stress induced by a wide
variety of physical and chemical agents (Huang et al.
1999).
To further this line of investigation, we decided to
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Figure 9 Components of Down syndrome phenotype present in persons with segmental trisomy 21. The regions of trisomy in JS and KJ,
indicated by the vertical bars, are quite similar to that present in the Ts65Dn mouse. Modified and reprinted, by permission, from Korenberg
et al. (1994). ( 1994 by the National Academy of Sciences, U.S.A.)
knock out Sod1, the gene for CuZn SOD. It should have
been easy—and the technical aspects of the homologous
recombination were—but when it came to generating a
Sod1 null mouse from our knockout heterozygotes, we
just could not seem to do it. Something was very wrong,
but, fortunately, Haru Sago, a visiting fellow from Japan,
found out what it was. In the course of generating the
knockout, my colleague Ting-Ting Huang had inadver-
tently produced a reciprocal translocation between the
end of chromosome 12 and the distal part of chromo-
some 16 just proximal to the knocked-out Sod1 gene
(Sago et al. 1998). This can be seen in the left panel of
figure 13 in which the Gart gene, which is distal to Sod1,
has moved—as the yellow arrow indicates—from end
of chromosome 16 to the end of chromosome 12,
whereas the more proximal App gene (fig. 13, middle
panel), is still on chromosome 16, where it belongs. This
was bad news for the SOD research—although Dr. Huang
subsequently did produce a usable Sod1 knockout—but
it was great news for the Down syndrome–model work.
We now had available to us the means to produce a mouse
with a second type of segmental trisomy 16, shown in
the panel on the right. This animal, which has been des-
ignated as Ts1Cje, has three copies of the Sod1 gene, one
of which has been knocked out, as well as of all of the
genes distal. It is, therefore, functionally trisomic for the
segment of mouse chromosome 16 distal to Sod1.
The reason that the serendipitous generation of this
mouse was so exciting is that it put us in the position
of at last being able to do what we really wanted to do,
and that was to use a subtractive approach to correlate
genes with effects. In this approach, we start with the
phenotype exhibited by the Ts65Dn mouse. We then
look at what happens to the phenotype when the degree
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Figure 10 Mouse fetus with trisomy 16 (Ts16; left) and diploid
littermate (2N; right). The small size, short snout, open eye lids, and
thick neck (the residual of midgestational edema) caused by trisomy
16 are visible. Picture provided by David Holtzman (Washington Uni-
versity, St. Louis).
Figure 11 Restoration of size of basal-forebrain cholinergic neu-
rons by infusion of nerve growth factor in aged Ts65n mice. The
decrease in cell-profile area in the nonoperated Ts65Dn mice is sig-
nificant at , and the increase in cell-profile area in treatedPp .009
Ts65Dn animals (vertical arrow) is significant at . ModifiedPp .02
and reprinted, by permission, from Cooper et al. (2001). ( 2001 by
the National Academy of Sciences, U.S.A.)
of trisomy is reduced, in this case from about 115 genes
in Ts65Dn to about 81 genes in Ts1Cje (fig. 14). I say
“about” because Roger Reeves (personal communica-
tion) has assured me that the numbers of genes change
daily, as annotation of the human and mouse genomes
proceeds. I favor the subtractive approach because it
begins with a defined phenotype and then looks at how
the phenotype changes when a particular gene or group
of genes is removed. This is in contrast to the transgenic
approach, which looks at the appearance of an abnormal
phenotype as extra genes are added. Because of the dif-
ficulties in controlling the location, copy number, and
regulation of transgenes, the findings are often difficult
to interpret.
We have used the subtractive approach in two exper-
imental systems so far. The first is with a test of spatial
learning carried out in the Morris water maze, a small
swimming pool in which a mouse seeks to locate a plat-
form hidden under the water. Several groups have stud-
ied Ts65 mice by this procedure, and the unanimous
conclusion has been that these animals are slow to learn
where the platform is located (Reeves et al. 1995; Cous-
sons-Read and Crnic 1996; Sago et al. 1998, 2000). This
is regarded as a defect in the function of the hippocam-
pus. Further, having finally learned where the platform
is, the trisomic mice then have great difficulty in learning
its new location when it is moved unbeknownst to them
to a new place. Rather than improve their performance
in repeated trials, as do diploid mice, the Ts65 mice tend
to perseverate and take nearly as long to find the relo-
cated platform in the last set of trials as they do in the
first. This is considered to involve an impairment of func-
tion of the hippocampus and prefrontal cortex. Using a
somewhat complicated breeding scheme, Elaine Carlson
and Haru Sago produced Ts65; Ts1; Ms1Ts65, the seg-
mental trisomy for the region of difference between the
[aforementioned] two; and euploid animals on the same,
albeit somewhat heterogeneous, genetic background (fig.
14) (Sago et al. 2000). The results were quite clear: the
performance of Ts1Cje mice in the maze was almost as
compromised as that of Ts65Dn, with the exception that
the Ts1Cje animals did a bit better in learning the lo-
cation of platform after it had been moved (fig. 15). By
contrast, the Ms1Ts65 animals, while certainly not nor-
mal, performed much better than did either of the two
other segmental trisomics. Therefore, it can be inferred
that the impaired performance in the water maze is
largely, but not entirely, the result of the imbalance of
genes distal to Sod1.
The second system in which Ts65 and Ts1 have been
compared is in the development of the skull and cranio-
facial skeleton, a process that is altered in a quite con-
sistent manner in trisomy 21 to produce the character-
istic appearance of Down syndrome. These studies were
done in collaboration with Joan Richtsmeier, at Penn
State, and Roger Reeves, at Johns Hopkins, who had
already set out to determine whether the morphogenic
abnormalities in the Ts65 mouse modeled those in hu-
mans with Down syndrome. Although mouse and hu-
man skulls look quite different from one another, they
do share the same overall bony architecture and have
the same landmarks. This makes it possible to compare
statistically the quantitative differences and similarities
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Figure 12 Association between CuZn SOD activity and life span. Although an association between elevated CuZn SOD activity and
prolongation of life in Drosophila has been observed, transgenic mice with threefold (hemi-Tg) and fivefold (homo-Tg) increased CuZn SOD
activity do not have an increased life span or an increased mean survival. Reprinted, by permission, from the Chicago Tribune and Huang et
al. (2000). ( 2000 by the Gerontological Society of America.)
between trisomic and nontrisomic skulls in humans and
mice. Thus, in the skull of a human with trisomy 21,
there is an overall reduction in the size of the skull, a
flattened occiput, brachycephaly, a small midface, re-
duced maxilla and mandible, and a reduced interorbital
distance. What Richtsmeier et al. (2000) found is that
Ts65 mice also have smaller skulls overall, with a dis-
proportionately reduced midface and anterior neuro-
cranium and a broader calvarium (fig. 16). Thus, as re-
markable as it seems, the changes, from normal, in the
shape of the skull that occur in the trisomic mouse di-
rectly parallel those seen in the skulls of persons with
Down syndrome. The similarity of the effects resulting
from imbalance affecting orthologous regions of the hu-
man and mouse genomes suggests that the genetic path-
ways determining the morphogenesis of the skull have
been evolutionarily conserved even as these two species
diverged. I take great comfort from this!
When Joan Richtsmeier went on to look at Ts1Cje
mice, she found that for more than 80% of these mea-
surements, the Ts1Cje’s differ (fig. 16, top, in red) or
resemble (in blue) their euploid littermates in ways very
similar to what had been found to define the differences
and similarities between Ts65Dn mice and their litter-
mates (fig. 16, bottom) (Richtsmeier et al., in press).
Although there are differences between Ts65Dn and
Ts1Cje, they are in the minority. Overall, what is altered
in the one is altered in the other. It would appear, there-
fore, that just as with the impairment in learning in the
Morris water maze, the craniofacial dysmorphology is
largely, but not entirely, the result of imbalance of the
genes distal to Sod1 on mouse chromosome 16.
Having narrowed down the region of major effects
on behavior in the water maze and formation of the
skull by about a quarter, where do we go from here?
Our present strategy is to extend the subtractive ap-
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Figure 13 Reciprocal translocation and the rise of Ts1Cje. The identification of the T1Cje translocation by FISH. The left and middle
panels identify the locations of Gart and App, respectively. Whereas the two App signals are located on chromosome 16, one of the more distal
Gart signals is located on chromosome 12, indicating the presence of a reciprocal 12;16 translocation with a breakpoint between the two
markers. In the trisomic Ts65Dn progeny of the balanced translocation carriers (right panel), there are three Sod1 signals, two on chromosome
16 and one on chromosome 12. The gene represented by the Sod1 signal on chromosome 12, which is at or just distal to the breakpoint, has
been knocked out by the same gene-targeting event that apparently caused the translocation. The figures, prepared as described by Sago et al.
(1998), were provided by Dr. Haru Sago.
Figure 14 The three currently existing segmental trisomies for
mouse chromosome 16. The numbers of genes in each trisomic segment
represent approximations, subject to change, that were provided by
Dr. Roger Reeves. Reprinted, by permission, from Epstein (2001). (
2001 by the McGraw-Hill Companies.)
proach by making a series of nested deletions in chro-
mosome 16 using the cre-lox approach and then to assess
their effects on defined components of the trisomic phe-
notype. This should ultimately permit us to determine,
by what will undoubtedly be an iterative process, which
genes are doing what.
Insofar as this is all directed to trying to understand
the genesis of Down syndrome, perhaps the greatest
problem that we will confront is that we cannot think
about cognition in a mouse in the same manner that we
think about cognition in humans, and we certainly can-
not speak about speech and language. Nevertheless, the
ways in which the brain works—the basic neural pro-
cesses that govern its ability to function and the genes
that control this—are very similar among the mammals.
In fact, conservation of function even between quite dis-
parate species is more the norm than the exception, and
neuroscientists have been willing to study these processes
in organisms as lowly as Aplysia, the sea slug. Therefore,
I believe that there is every reason to expect that the
perturbations of form and function found in the trisomic
mice are relevant to trisomic humans. [Following deliv-
ery of the Allan Award address, Eric Kandel’s Nobel
Prize essay was published {Kandel 2001}. In this essay,
Kandel makes several comments that are supportive of
my point of view. Of note is his assertion, characterized
as a leap of faith, that elementary forms of learning are
common to all animals with an evolved nervous system.
This belief has been bolstered by his findings that dif-
ferent forms of learning present in a simple invertebrate
are paralleled by corresponding forms of learning in
higher vertebrates and humans and that there is con-
servation of the relevant biochemical mechanisms. There-
fore, if it is possible to consider an invertebrate to be a
legitimate model for learning and memory in humans,
it certainly requires a much smaller leap of faith to place
the mouse in this role.]
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Figure 15 Latency (time to reach platform) in reverse hidden-
platform test in the Morris water maze. The best performance is by
2N animals, and the poorest performance is by Ts65Dn. The per-
formance by Ts1Cje is somewhat better than that by Ts65Dn, whereas
that by Ts1Cje is better than that by the other two segmental trisomics
but still not as good as that by the 2N mice. All mice were generated
from the same Ts65Dn # T1Cje cross. Modified and reprinted, by
permission, from Sago et al. (2000). ( 2000 by the International
Pediatric Research Foundation, Inc.)
Figure 16 Comparison between skulls of Ts1Cje (top) and Ts65Dn (bottom) mice, demonstrating that there is a similar shortening of distances
between landmarks (numerals) relative to diploid controls in the two segmental trisomics. Modified and reprinted, by permission, from Reeves et
al. (2001) ( 2001 by Elsevier Science) and Richtsmeier et al. (in press) ( 2001 by Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.).
In a curious way, our problem at this time is more on
the human than on the mouse side. Despite [a] the length
of time that Down syndrome has been known as an
entity and studied and [b] the elegance of the methods
for studying the nervous system that have been devel-
oped, we actually know very little about what is ab-
normal about the brains and nervous systems of people
with Down syndrome—about whether, for example,
there are abnormalities of the retrograde transport of
NGF or of long-term potentiation and depression or
even of pain perception—all of which are abnormal in
the mouse (Cao et al. 1999; Martinez-Cue et al. 1999;
Siarey et al. 1999; Cooper et al. 2001). This is not really
surprising, because our hands seem to be very much tied
when it comes to studying what is happening within the
black box of the human cranium. Perhaps one benefit
of working with the mouse will be to point our attention
to relevant problems that need to be studied in humans
and force us to develop methods for doing so.
I now want to return to the Allan Award lecture given
by Jerome Lejeune in 1969 (Lejeune 1970). Since I was
the local organizer for that meeting, I was charged with
taking Lejeune to dinner. What should have been an
enjoyable experience for me turned out to be less than
pleasurable. I had just started the prenatal-diagnosis pro-
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Figure 17 The challenge facing human geneticists, as articulated
by Epstein (1997).
Figure 18 The challenge facing human geneticists, with consid-
eration of the human being entered into the balance.
gram at UCSF and thought that it would be a boon to
genetic counseling. Lejeune, believing that human life
begins at conception and strenuously opposed to abor-
tion, thought otherwise, and he forcefully articulated his
position both at dinner and the next day in his Allan
Award address that turned out to be the second earth-
quake of the meeting. With obvious reference to those
who were promoting prenatal diagnosis, he described
what he called “The National Institute of Death … a
new facility for research and applied eugenics” (Lejeune
1970). As stipulated in Article II.E, the function of this
institute was to “destroy, delete, or decry any human
condition” deemed undesirable and any embryos “not
fitting standard requirements.” He concluded his talk by
asking, “Should we capitulate in the face of our own
ignorance and propose to eliminate those we cannot
help?” It was strong rhetoric—especially since he in-
voked the dreaded notion of eugenics—but I was not
persuaded and went on about my business.
Now, more than 30 years later, I still do not believe
that we are engaged in eugenics in the sense that Lejeune
implied, although it is certainly true that we seek to help
people have children who are indeed well born—which
is the literal meaning of “eugenic.” However, by virtue
of my research on Down syndrome, I have been very
much involved with volunteer organizations—the Na-
tional Down Syndrome Society, in particular—that have
an interest in promoting the welfare of persons with
Down syndrome, and this involvement has given me
personal contact with literally hundreds of people with
Down syndrome, of all ages, and with their families.
Furthermore, I have also dealt, in the clinic, with patients
and families confronting an enormous variety of disa-
bilities and have interacted with organizations repre-
senting their interests. Even though I do not regard abor-
tion as the most desirable way to prevent genetic
diseases, none of these encounters has dissuaded me
from the belief that prospective parents should have the
right to exercise the options that prenatal diagnosis
makes possible.
However, I must say that, with time, I have become
more sensitive to many of the concerns of Lejeune and
others about the applications of modern genetics and be-
lieve that we need to be more attuned to the messages
that are implicit in our various programs for the preven-
tion of genetic disorders. The disability-rights movement
asserts that the willingness to terminate a pregnancy be-
cause of fetal abnormality constitutes a rejection of those
who have such an abnormality and, in the extreme, a
denial of their very right to exist (Parens and Asch 1999).
I do not go along with this position, but I do think that
we need to listen to what is being said about how people
with disabilities, genetic and otherwise, feel they are being
regarded. The fact that we have state-supported maternal
serum-screening and prenatal-diagnosis programs that are
justified on the basis of cost:benefit calculations—dollars
per trisomic fetus detected or prevented (i.e., aborted)—
says a great deal about how we, as geneticists and a so-
ciety, view Down syndrome and the other conditions for
which we screen (Cunningham and Tomkinison 1999).
As much as we talk about neutrality and nondirectiveness
in genetic counseling, the message that these programs
convey is that it is really not all right to give birth to a
child with serious abnormalities.
Why have I have juxtaposed these troublesome
thoughts about prenatal diagnosis and disability rights
to a description of my research into the mechanisms by
which extra chromosomes cause their deleterious effects?
My reason is quite simple: It is to remind us that the
operative word in “human genetics” is “human.” Hu-
man genetics is about human beings—about humanity
and humaneness.
In my Presidential Address in 1996, I described the
challenge facing human geneticists as being to find the
proper balance between the hopes and fears of society
and the goals and interests of our science in discovering
new knowledge, improving health, and curing disease
(fig. 17) (Epstein 1997). The current debate over cloning
and stem cells is a perfect case in point. Now I want to
broaden the challenge to add a third element to the
balance—the individual, the human being—whose per-
sonal interests, whether as an affected patient, a parent
of an abnormal fetus, or a clinically normal person, may
or may not be consonant with the interests of govern-
ment, business, the genetic establishment, or society at
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large (fig. 18). With the major push toward the devel-
opment and patenting and marketing of genetic tests and
products, which many—certainly those who write in the
business pages of the newspapers—seem to think the post-
genomic era is all about, the individual already stands the
risk of becoming merely grist for the mill—the consumer
to be targeted. With the ever-increasing power of geno-
mics, transgenesis, and manipulative reproductive tech-
nologies, the stakes are becoming even greater. There is
no question that the potential for doing good is increasing,
but so is the potential to do harm. In the end, and perhaps
with greater urgency in these perilous times in which we
now find ourselves, it is the human being that must be
our ultimate point of reference.
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